Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).

Inclusion Criteria: * patients between 18 and 70 years * parenchymal pulmonary involvement at Chest X-Ray (CXR) AND one of the follows: physiologic abnormalities on pulmonary function testing and/or respiratory symptoms, and/or exercise-induced abnormalities. Exclusion Criteria: * Unable to understand protocol and to sign informed consent or not suitable candidate to comply with the requirements of this study, in the opinion of the investigator * Cardiac and neurological sarcoidosis or any other organ involvement * End stage lung disease at high-resolution computed tomography (HRCT) * Clinical evidence of active infection * Documented exposure to beryllium * Patients with Forced Expiratory Volume at one second (FEV1) changes after salbutamol inhalation ≥20% * Comorbidity: advanced liver cirrhosis or abnormal liver function, unstable cardiac disease, moderate to severe renal insufficiency, poorly controlled diabetes * Pregnancy or lactation * A tuberculin skin test (5 I.U.) more than 5 mm * Psoriasis * Homozygous glucose-6-phosphatase deficiency * Known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives * Visual field changes attributable to 4-aminoquinolines * Concomitant therapies: any patient enrolled in the study must be off all prohibited medications at least 4 weeks before screening. Once patients completed the washout period, they may enter the screening period that may last up to 30 days * Previous therapies: any patient enrolled must be off all medications for sarcoidosis at least 4 weeks before screening.